IP Library Granted Patent US 11,578,328
Granted Patent B2
US 11,578,328 · App. 16/988,226 · Granted Feb 14, 2023

Interfering RNA molecules

Inventors: Klaus Giese (Berlin, DE); Jörg Kaufmann (Berlin, DE); Anke Klippel-Giese (Berchtesgaden, DE)
Assignee: Silence Therapeutics GMBH
C12N15/1137A61K31/713C12N5/10C12N15/111C12N15/113C12Q1/68C12Y207/11001A61K38/00C12N2310/14C12N2310/3183C12N2310/32C12N2310/321C12N2310/322C12N2310/343C12N2310/346C12N2310/3521C12N2310/3525C12N2310/53C12N2310/531C12N2320/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,578,328
App. No.
16/988,226
Granted
Feb 14, 2023
Kind
B2
Abstract

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.

Claims (17)

1. A double-stranded siRNA molecule wherein:

(i) at least one strand of the double-stranded siRNA molecule comprises one or more groups of modified nucleotides and one or more groups of flanking nucleotides, the flanking nucleotides being on one or both sides of the modified nucleotides, wherein:

the one or more groups of modified nucleotides have an amino, fluoro, alkoxy, or alkyl modification at the 2′-position; and

the one or more groups of flanking nucleotides have an amino, fluoro, alkoxy, or alkyl modification at the 2′-position, the modification at the 2′-position of the flanking nucleotide being different from the modification at the 2′-position of the modified nucleotide; and

(ii) the number of nucleotides in the one or more groups of modified nucleotides is 1-10 and the number of nucleotides in the one or more groups of flanking nucleotides is 1-10.

2. The ribonucleic acid according to claim 1 , wherein the double-stranded siRNA molecule has a double-stranded region of 17-21 nucleotides in length.

3. The ribonucleic acid according to claim 1 , wherein the double-stranded siRNA molecule is capable of RNA interference.

4. The double-stranded siRNA molecule of claim 1 , wherein the double-stranded region is at least 18 nucleotides in length.

5. The double-stranded siRNA molecule of claim 1 , wherein the alkoxy modification at the 2′-position of the one or more groups of modified nucleotides or the one or more groups of flanking nucleotides is a methoxy modification.

6. The double-stranded siRNA molecule of claim 1 , wherein the at least one strand of the double-stranded siRNA molecule is the antisense strand.

7. The double-stranded siRNA molecule of claim 1 , wherein at least one of the strands has an overhang of at least one nucleotide at the 3′-end.

8. The double-stranded siRNA molecule of claim 1 , wherein the strand having the overhang at the 3′-end is the antisense strand.

9. The double-stranded siRNA molecule of claim 1 , wherein the one or more groups of modified nucleotides have an alkoxy modification at the 2′-position, the alkoxy modification being a methoxy modification.

10. The double-stranded siRNA molecule of claim 1 , wherein the one or more groups of flanking nucleotides have a fluoro modification at the 2′-position.

11. The double-stranded siRNA molecule of claim 1 , wherein the one or more groups of modified nucleotides are located on at least alternating nucleotide positions over the length of the at least one strand.

12. The double-stranded siRNA molecule of claim 1 , wherein the double-stranded siRNA molecule inhibits the expression of a target nucleic acid.

13. A method for inhibiting the expression of a target gene in a cell comprising introducing a ribonucleic acid according to claim 1 into the cell in an amount sufficient to inhibit expression of the target gene, wherein the target gene is the target gene of the a ribonucleic acid according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2020
From: GIESE, KLAUS; KAUFMANN, JÖRG; KLIPPEL-GIESE, ANKE
To: ATUGEN AG
Reel/Frame 054071/0583 →
CHANGE OF NAME Recorded Oct 15, 2020
From: ATUGEN AG (AKTIENGESELLSCHAFT)
To: SILENCE THERAPEUTICS AKTIENGESELLSCHAFT (AG)
Reel/Frame 054071/0627 →
CHANGE OF NAME Recorded Oct 15, 2020
From: SILENCE THERAPEUTICS AG
To: SILENCE THERAPEUTICS GMBH
Reel/Frame 054091/0465 →
Priority Claims (2)
EP 02017601 · Aug 5, 2002 · regional
EP 03008383 · Apr 10, 2003 · regional
Continuity (11)
Continuation 16403373 · May 3, 2019
Continuation 16122827 · Sep 5, 2018
Continuation 15678024 · Aug 15, 2017
Continuation 15589968 · May 8, 2017
Continuation 14977710 · Dec 22, 2015
Continuation 14578636 · Dec 22, 2014
Continuation 13692178 · Dec 3, 2012
Continuation 12986389 · Jan 7, 2011
Continuation 12200296 · Aug 28, 2008
Continuation 10633630 · Aug 5, 2003
Related Publication 20210062198A1 · Mar 4, 2021